Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials
0 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals155 enrolled14 locationsNCT07190300
Recruiting
Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Ankara Etlik City Hospital102 enrolled2 locationsNCT07181122
Recruiting
Not Applicable
Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano566 enrolled3 locationsNCT05649943
Recruiting
Phase 3
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet750 enrolled32 locationsNCT03903835
Recruiting
Phase 3
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT05956639